Advancing cervical cancer treatment: integrating immunotherapy with chemoradiotherapy

Introduction Cervical cancer (CC) represents a significant public health challenge worldwide, ranking as the fourth most common cancer among women1,2. This disease mainly results from a chronic infection with the human papilloma-virus (HPV), impacting over half a million women worldwide and leading to roughly 300 000 fatalities3. Incidence and mortality rates of CC are disproportionately high in LMICs, highlighting the urgent need for enhanced screening and vaccination programs in these regions3,4. Despite significant progress in screening and HPV vaccination, these areas continue to face high incidences of the disease. This highlights a critical need for more effective treatment strategies. In this context, immunotherapy, particularly when used in conjunction with conventional chemoradiotherapy (CRT), has emerged as a potential path. This approach offers potential for improved treatment outcomes and revives hope for those battling high-risk, locally advanced CC4,5. The evolution of CC treatments: emphasizing immunotherapy The incorporation of immunotherapy into traditional treatment protocols represents a major advancement in CC care. This innovative approach is especially effective in treating high-risk, locally advanced, recurrent, persistent, or metastatic cervical cancer (PMCC), conditions where conventional treatments frequently prove inadequate. By targeting specific cancer cells or boosting overall immune response, it can address CC cases that are resistant to standard treatments like surgery, radiation, or chemotherapy6. The advent of immune checkpoint inhibitors has transformed treatment paradigms by blocking proteins that prevent the immune system from attacking cancerous cells, offering new hope for better patient outcomes7. These therapies, by utilizing immune system targets and destroys carcinogenic cells, have shown promising results in clinical trials, establishing new benchmarks for efficacy and survival rates. As research progresses, combining immunotherapy with conventional methods such as chemoradiotherapy is proving to be an effective strategy, potentially redefining the standards of care in CC management and offering patients a chance for a better quality of life and longer survival5. The revolution in CC management is significantly marked by the advent of immune checkpoint inhibitors like Pembrolizumab, Nivolumab, and Atezolizumab, which has led to a new era in the treatment of this malignancy8. Pembrolizumab, a PD-1 inhibitor, has demonstrated notable efficacy in treating CC, especially in cases that are persistent, recurrent, or metastatic and exhibit PD-L1 positivity. This breakthrough was accelerated by the durable antitumor activity witnessed in clinical trials, catalyzing a shift toward immunotherapy-centric treatment paradigms9. Both Nivolumab and Atezolizumab has also been explored for its effectiveness in CC through clinical trials. The integration of such advanced immunotherapies with traditional methods, is reshaping the landscape of CC management, offering renewed hope to patients dealing with high-risk and advanced stages of this disease10. Combining immunotherapy with CRT The rationale for integrating immunotherapy with chemoradiotherapy in CC management is deeply rooted in CRT’s inherent ability to stimulate the immune system. Traditionally, CRT, which combines external beam radiotherapy with concurrent chemotherapy, has been a fundamental treatment for locally advanced CC6. The addition of immunotherapy to this regimen aimed at enhancing the immune response initiated by CRT, with the goal of overcoming the immune evasion mechanisms often utilized by CC cells, a phenomenon largely attributed to HPV infections. This innovative approach is currently being evaluated through various clinical trials, which have shown promising results in terms of both safety and efficacy5. These preliminary findings suggest a potential shift towards more integrated treatment strategies for high-risk, locally advanced CC, offering hope for improved outcomes by leveraging the synergistic effects of immunotherapy and CRT (Table 1). Table 1 - Summarizes key studies on the integration of immunotherapy in CC treatment. Author(s), Year Study component Key insights Limitations (if any) Rodrigues M. et al., 202314 The authors discussed the NiCOL trial, which was used to assess the safety profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with LACC Nivolumab plus CRT is safe with encouraging PFS rates. Further validation in CC with immune activation is warranted Small sample size (16 women with LACC) GrauBéjar J.F. et al., 20237 The review findings suggest that a comprehensive examination of the major treatment advances in the field of immunotherapy for CC. The authors discuss the most innovative immunotherapy approaches currently in early clinical development for advanced CC Immunotherapy advancements show promising efficacy in CC treatment. Immune checkpoint inhibitors have transformed the treatment landscape. Dismal prognosis for recurrent, persistent, or metastatic disease Modest outcomes in LACC Polten R. et al., 202215 In this study, the author explored the strengths and limitations of both standard and developing treatment approaches for CC. Immunotherapeutic approaches show potential for treating CC. Increased understanding of disease biology and etiology Damage to healthy tissues due to the ‘ontarget, offtumor’ effect. Limited selectivity of CAR therapy for tumor cells presents a challenge Yang X. et al., 20225 The study described the rationale for combining radiotherapy with immunotherapy in patients with cervical cancer Radiotherapy combined with immunotherapy shows synergistic effects in CC. Integration of radiotherapy and immunotherapy in CC treatment is promising Lack of clinical data to validate mathematical models Song Z. et al., 202216 The author in this research reviewed the progress of immune checkpoint blockade (ICB) therapy LACC and RMCC. The study compares ICB with other treatment modalities Immunotherapy shows safety and some efficacy in LACC and R/MCC. Large clinical trials needed for more treatment options and patient screening Limited efficacy of firstline treatments for LACC and R/MCC Need for additional large multicentre clinical trials for immunotherapy Ge Y. et al., 202217 In this article, the author provides an overview of antiPD1/PDL1based immunotherapy in the treatment of CC. The discussion includes how these new combined therapies enhance the therapeutic benefits Offered a summary of antiPD1/PDL1based immunotherapy in cervical cancer treatment.Discussed strategies that combine PD1/PDL1 inhibitors with various immunotherapies to enhance efficacy Limited and inadequate therapeutic options for advanced and recurrent CC patients. Relatively low response rate of pembrolizumab in treating CC Daro M. et al., 202218 The study demonstrated that the use of IGIMRT and 3DIGABT has significantly enhanced treatment outcomes and toxicity profiles for patients LACC, the gold standard in many countries CCRT increases levels of multiple soluble immune checkpoint proteins. Higher sLAG3 levels in poor responders to CCRT Heterogeneous effects induced by CRT across studies. Best timing for immunotherapy unclear from current data Pang S. et al., 202219 The article suggested that the typical treatment for cervical cancer involves combination chemotherapy and the use of bevacizumab. Recent data also indicate benefits from adding upfront immunotherapy for women whose cancer expresses programmed death ligand1 Singleagent cisplatinbased chemotherapy concurrent with radiation is the mainstay of treatment for LACC. Combination chemotherapy, bevacizumab, and upfront immunotherapy are used for metastatic CC Physical sequelae from pelvic irradiation Psychologic challenges related to stigma and sexual dysfunction Liu M.C. et al., 20229 In the study, the use of immunotherapy in cervical cancer treatment is examined, including its mechanisms, predictive biomarkers for treatment response, and processes of tumor resistance or escape Pembrolizumab approved for firstline and secondline CC treatment. Cemiplimab is expected to receive approval for treating recurrent or metastatic cervical cancer Limited available treatments for advanced CC. Concerns about secondary tumoral escape or resistance to immunotherapy Schmidt M. et al., 202220 The article revealed that strong evidence supporting the effectiveness of treatments for recurrent or metastatic CC is currently limited to pembrolizumab combined with chemotherapy and bevacizumab Pembrolizumab combined with chemotherapy and bevacizumab has proven to be effective. There is a critical need for extensive confirmatory trials on alternative immunotherapies Limited strong evidence on efficacy of alternative immunotherapies Few comparative trials, potential bias in noncomparative trials These studies explore a range of topics, from the safety and efficacy of trial to broader reviews of immunotherapy advances. Innovative immunotherapeutic approaches The treatment landscape for CC is experiencing a significant change with the introduction of innovative immunotherapeutic approaches. Immune checkpoint inhibitors such as Pembrolizumab, Nivolumab, and Atezolizumab are leading this revolution10. These agents target PD-1/PD-L1 proteins used by cancer cells to evade immune detection, effectively reactivating the patient’s immune response against the tumor8. Pembrolizumab, specifically approved for PD-L1 positive cases, has shown promising survival benefits. Alongside, adoptive cell transfer uses tumor-infiltrating lymphocytes from the patient’s own tumor, expanding them in vitro, and reintroducing them to strengthen a robust antitumor response, with clinical trials validating their safety and efficacy. Further enriching the therapeutic options are therapeutic cancer vaccines and oncolytic virus therapy11. Cancer vaccines are being developed to provoke the immune system to target HPV related antigens, potentially stopping the progression of HPV-positive CCs. Oncolytic viruses, like T-VEC, selectively infect and destroy cancer cells while initiating an immune response against the tumor, a dual action that not only reduces the tumor load but also primes the immune system12. The integration of these immunotherapies with standard CRT is particularly promising; this combined strategy aims to reduce the immunosuppressive tumor microenvironment and enhance the immune-mediated eradication of cancer cells. This cooperative approach could significantly improve the management of locally advanced CC, paving the way for more effective and lasting treatment outcomes. Setting new standards: immunotherapy in first-line treatment The integration of immunotherapy into the first-line treatment of recurrent or metastatic CC represents a significant advancement13. Trials like KEYNOTE-826 have established new standards of care, combining pembrolizumab with chemotherapy and, in some cases, bevacizumab. This combination has not only shown efficacy in improving survival rates but also in setting a precedent for the use of immunotherapy in the initial management of advanced CC9. Despite these advancements, challenges remain in the widespread adoption of immunotherapy in CC treatment. Identifying the ideal patient populations, managing adverse effects, and addressing issues of accessibility and affordability, especially in resource-constrained settings, are critical concerns that need to be addressed. Moreover, understanding the intricate immune landscape of CC and the mechanisms of action of immunotherapies is essential for optimizing treatment strategies and enhancing patient outcomes10. Conclusion The integration of immunotherapy into the treatment regimen for CC marks a pivotal advancement in combating this prevalent disease. The innovative use of immune checkpoint inhibitors alongside traditional CRT, offers a promising path toward more effective and personalized care. These therapies not only enhance the body’s immune response but also target the unique immunological evasion tactics employed by tumor cells associated with HPV infections. As these strategies continue to be refined through clinical trials, they hold the potential to substantially improve survival rates and quality of life for patients with high-risk, locally advanced cervical cancer. This evolving treatment landscape not only underscores the critical role of immunotherapy in care but also highlights the necessity for ongoing research and adaptation of treatment protocols to optimize patient outcomes in various demographic settings. Ethical approval Not applicable. Consent Informed consent was not required for this study. Source of funding Not applicable. Author contribution All authors have contributed significantly. Conflicts of interest disclosure Not applicable. Research registration unique identifying number (UIN) Not applicable. Guarantor Edward Mawejje. Data availability statement Not applicable to this article. Provenance and peer review Not commissioned, externally peer-reviewed.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.